BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
申请人:Gilead Sciences, Inc.
公开号:US20160333009A1
公开(公告)日:2016-11-17
The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I:
or pharmaceutically acceptable salts thereof, in which X, L, n, m, R
1
, R
2a
, R
2b
, R
n
, R
m
, and R
t
are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.
本公开提供了式I的吲哌酮2,3-二氧化酶1(IDOL)抑制剂:
或其药学上可接受的盐,其中X、L、n、m、R
1
、R
2a
、R
2b
、R
n
、R
m
和R
t
如本文所定义,以及包括式I化合物的药物组合物,或其药学上可接受的盐,并使用这些方法来治疗由IDO1介导的疾病。
12-EPI PLEUROMUTILINS
申请人:NABRIVA THERAPEUTICS AG
公开号:US20160332963A1
公开(公告)日:2016-11-17
A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula
processes for the preparation of such compounds and their use as pharmaceuticals.
Molecular‐Level Overhaul of γ‐Aminopropyl Aminosilicone/Triethylene Glycol Post‐Combustion CO
<sub>2</sub>
‐Capture Solvents
作者:David C. Cantu、Deepika Malhotra、Manh‐Thuong Nguyen、Phillip K. Koech、Difan Zhang、Vassiliki‐Alexandra Glezakou、Roger Rousseau、Jordan Page、Richard Zheng、Robert J. Perry、David J. Heldebrant
DOI:10.1002/cssc.202000724
日期:2020.7.7
power plant, albeit only if high solution viscosities and hydrolysis of the siloxane moieties can be mitigated. This study concerns an integrated multidisciplinary approach to overhaul the GAP/TEG solvent system at the molecular level to mitigate hydrolysis while also reducing viscosity. Cosolvents and diluents are found to have negligible effects on viscosity and are not needed. This finding allows for
Integrated capture and conversion of CO2 to methanol or methanol and glycol
申请人:Battelle Memorial Institute
公开号:US10961173B2
公开(公告)日:2021-03-30
A process for producing methanol includes combining a hydrogenation catalyst, hydrogen, and CO2 with a condensed phase solution comprising an amine under conditions effective to form methanol and water. A process for coproduction of methanol and a glycol includes combining an epoxide, a hydrogenation catalyst, hydrogen, and CO2 with a condensed phase solution comprising an amine under conditions effective to form methanol and a glycol.
The present invention is the following Amphotericin B derivative:
wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.
本发明是以下两性霉素 B 衍生物:
其中各符号在说明中定义。本发明化合物的第 16 位(X)是脲结构、环状结构、羟烷基或取代的单烷基氨基甲酰基。本发明化合物具有抗真菌活性。